Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients : theguardian
as declared in theguardian
Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients
Trial shows tantalising signs that new Alzheimer's drug could benefit early-stage patients
A trial of a new Alzheimer's drug has shown it could benefit patients in the earliest stages of the disease, raising hopes that a treatment for the devastating condition may finally be on the horizon.While the trial was designed to assess the safety of the treatment and not whether patients fared better on the drug, an "exploratory analysis" of the data revealed that the treatment appeared to slow the mental decline of patients who responded to the therapy.The small study of only 165 people with mild symptoms of the disorder found that a dozen monthly injections of the antibody aducanumab removed clumps of protein that build up in the Alzheimer's brain.
in the same way independent
Alzheimer's disease breakthrough as new drug clears toxic proteins from brains of patients
Alzheimer's disease breakthrough as new drug clears toxic proteins from brains of patients
An antibody that can almost completely clear the visible signs of Alzheimer's disease from the brain has been discovered in a breakthrough that left one scientist "trying not to get too excited".Researchers scanned the brains of people with the degenerative condition as they were given doses of the drug, which is based on an immune cell taken from the blood of elderly people aged up to 100 who showed no signs of the disease.After a year, virtually all the toxic "amyloid plaques" that build up in Alzheimer's patients appeared to have gone from the brains of those given the highest doses of the antibody.
by the same token on upi
FDA approves new biological drug for rheumatoid arthritis
FDA approves new biological drug for rheumatoid arthritis
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug AdministrationThe drug Erelzi (etanercept-szzs) is a "biosimilar" to Enbrel (etanercept), which was approved by the FDA in 1998.A biosimilar is a biological product approved on findings that it is highly similar to an already-approved biological product and has no clinically meaningful differences in terms of safety and effectiveness, according to the FDA.It is similar to generic drugs in that it typically costs less than the original biological product.
by the same token on express
'Game-changing' new drug could STOP progression of ALZHEIMER'S
'Game-changing' new drug could STOP progression of ALZHEIMER'S
GETTY A new drug which stops Alzheimer's disease in its tracks is to receive widespread human trialsScientists have been so impressed with the antibody therapy known as 'aducanumab', they are keen to move the trials on from mice to human beings.They believe the drug could be the first stepping stone to finding a cure for the, as yet, incurable condition.Hailed as a major breakthrough, medics found that the new drug slows or stops altogether the progression of the disease.
Comments
Post a Comment